Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

T. Klopfenstein,a,1,* S. Zayet,a,1,* A. Lohse,b J.-C. Balblanc,b J. Badie,c P.-Y. Royer,a L. Toko,a C. Mezher,c N.J. Kadiane-Oussou,a M. Bossert,b A.-M. Bozgan,b A. Charpentier,b M.-F. Roux,d R. Contreras,d I. Mazurier,e P. Dussert,e V. Gendrin,a T. Conrozier,b
For the HNF Hospital Tocilizumab multidisciplinary team

A R T I C L E   I N F O
Article history:
Received 29 April 2020
Accepted 4 May 2020
Available online 6 May 2020

Keywords:
Tocilizumab
COVID-19
SARS-CoV-2
Mortality
Intensive care unit

A B S T R A C T
Introduction. – No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.
Method. – We conducted a retrospective case–control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions.
Results. – Patients with TCZ (n = 20) had a higher Charlson comorbidity index (5.3 [±2.4] vs 3.4 [±2.6], P = 0.014), presented with more severe forms (higher level of oxygen therapy at 13 L/min vs 6 L/min, P < 0.001), and had poorer biological findings (severe lymphopenia: 676/mm³ vs 914/mm³, P = 0.037 and higher CRP level: 158 mg/L vs 105 mg/L, P < 0.001) than patients without TCZ (n = 25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, P = 0.002).
Conclusion. – Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.

© 2020 Elsevier Masson SAS. All rights reserved.

1. Introduction
Coronavirus disease 2019 (COVID-19) is now a huge medical issue around the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a high mortality rate, for example 28% of 191 hospitalized patients in two hospitals in Wuhan, China [1]. Around the world intensive care unit (ICU) capacities are challenged to face this outbreak [2]. No therapy has yet been proven effective [3]. Data is particularly needed on treatments able to reduce mortality and the number of critical ill patients [4].

Death mainly results from acute respiratory distress syndrome (ARDS) [5]. Markers of inflammation such as C-reactive-protein (CRP), ferritin, and interleukin–6 are significantly associated with mortality [6,7]. COVID-19–related multiple–organ failure and ARDS are mainly caused by cytokine storm [8]. Post-viral hyperinflammation with onset on the second week of the disease mostly seems to explain disease severity [9]. Tocilizumab (TCZ) is a recombinant humanized anti-interleukin–6 receptor (IL-6R) monoclonal antibody used in the treatment of rheumatoid arthritis. Several arguments show that TCZ administered to patients with severe COVID-19 could be an effective treatment to reduce mortality. By neutralizing a key inflammatory factor in the cytokine release syndrome (CRS), this molecule may block the cytokine storm during the systemic hyperinflammation stage and reduce disease severity [10,11]. To our knowledge, there is no evidence of TCZ ability to reduce the number of COVID–19 severe cases and/or mortality. We aimed to compare the outcome, especially ICU admissions and/or mortality, between COVID–19 patients treated with TCZ and without TCZ.

* Corresponding author.
E-mail addresses: timothee.klopfenstein@hnf.fr (T. Klopfenstein), souhail.zayet@gmail.com (S. Zayet).
1 The first and second authors (T.K. and S.Z.) made equal contributions.
https://doi.org/10.1016/j.medmal.2020.05.001
0399-077X/© 2020 Elsevier Masson SAS. All rights reserved.
2. Method

We conducted a retrospective case-control study in NFC (Nord Franche-Comté) Hospital. On March 1, a first case of COVID-19 was confirmed in our hospital. "Standard treatment" was offered to patients requiring oxygen therapy: hydroxychloroquine or lopinavir-ritonavir therapy and antibiotics, and less commonly corticosteroids. On April 1, in relation with the increasing medical literature data, the NFC hospital scientific medical committee including infectious disease specialists, ICU specialists, rheumatologists, biologists, and pharmacists, approved the off-label use of TCZ in patients with general status deterioration despite well-conducted standard care. Daily "tocilizumab multidisciplinary team meetings" were organized to discuss patients' eligibility to receive TCZ. Based on the medical literature, we checked several criteria before starting TCZ treatment: no contraindication to TCZ, confirmed COVID-19 with SARS-CoV-2 RT-PCR, failure of standard treatment, time to symptom onset ≤ 7 days, oxygen therapy > 5 liters/min, > 25% of lung damages on chest computed tomography (CT) scan, and ≥ 2 parameters of inflammation or biological markers of mortality (with a high level) such as ferritin, CRP, D-dimers, lymphopenia, and lactate dehydrogenase. As false-negative SARS-CoV-2 RT-PCR results may be observed during the second week, we suggested treating high suspicion of COVID-19 with obvious clinical, biological, and imaging (chest CT-scan) data and without differential diagnosis despite a negative SARS-CoV-2 RT-PCR result after multidisciplinary discussion.

The present work compares two groups of patients.

The "tocilizumab group" (TCZ group) included all patients who received standard treatment and tocilizumab (1 or 2 doses). Between April 1 and April 13, 2020, we enrolled all adult patients who received TCZ for confirmed COVID-19 by SARS-CoV-2 RT-PCR or diagnosis confirmed during the tocilizumab multidisciplinary team meeting. All patients receiving tocilizumab were informed that this prescription was used outside of its marketing authorization indications, and that their anonymized medical data would be used for a retrospective medical study. Patients were also informed that they could deny study participation.

The standard treatment group (ST group) included patients receiving standard treatment but without tocilizumab. This group included all hospitalized adult patients with confirmed COVID-19 by SARS-CoV-2 RT-PCR between March 1 and March 18, 2020. Because patients from the TCZ group were all critically ill patients and for comparable population purposes in the two groups, we excluded from the control group patients with moderate disease (i.e. those hospitalized for less than 48 hours and/or who did not receive the standard treatment and/or oxygen therapy). We also excluded patients with treatment not routinely administered in our hospital such as remdesivir and immunoglobulins.

In all patients, diagnosis of COVID-19 was confirmed by real-time RT-PCR on respiratory samples. Briefly, viral RNA was extracted using the Nucleospin® RNA Virus kit (Macherey-Nagel) according to the manufacturer's instructions, and amplified by RT-PCR protocols developed by the Charité (E gene) [12] and the Institut Pasteur (RdRp gene) [13] on LightCycler 480 (Roche).

We collected the following data from the medical files of patients in both groups: demographic characteristics, comorbidities, clinical and paraclinical characteristics of the infection, and outcome.

To increase statistical power, we chose a combined primary endpoint (death and/or ICU admission) to compare the two groups. Continuous variables were expressed as mean and standard deviation (SD) and compared with ANOVA test. Categorical variables were expressed as number (%) and compared by χ² test or Fisher's exact test between the two groups. A P-value < 0.05 was considered significant. We used the SPSS v24.0 software (IBM, Armonk, NY, USA).

3. Results

We included 20 patients in the TCZ group. Twenty-one patients were treated with TCZ between April 1 and April 13, 2020. One patient was excluded because he received a non-standard treatment (IV immunoglobulins). We included 25 patients in the ST group. Fifty-nine patients with confirmed COVID-19 were hospitalized between March 1 and March 18, 2020. Thirty-four patients hospitalized for less than 48 hours or without standard treatment were excluded (11 and 23, respectively).

No statistical differences were observed between the two groups (TCZ and ST) with regard to age, sex, and comorbidities (Table 1). However, TCZ patients had a higher Charlson comorbidity index than non-TCZ patients (5.3 [± 2.4] vs 3.4 [± 2.6]; P = 0.014), and patients aged above 70 years were more frequent in the TCZ group than in the ST group (75% vs 44%, P = 0.036).

No statistically significant between-group difference was observed in terms of clinical features on admission. However, during hospitalization, oxygen requirement (flow and duration) was higher in the TCZ group than in the ST group (respectively, 13L/min vs 6L/min, P = 0.001 and 12 days vs 4 days, P = 0.009). Biological findings on admission were statistically more severe in the TCZ group than in the ST group for lymphopenia (676/mm³ vs 914/mm³, P = 0.037) and CRP level (158 mg/L vs 105 mg/L, P = 0.017). However, lung involvement on CT scan at admission did not seem different, but we noticed that only 2/8 patients in the ST group had > 50% lung involvement on CT scan (17/25 patients in the ST group did not have a CT scan performed at admission).

Our combined primary endpoint (death and/or ICU admission) was higher in the ST group than in the TCZ group (72% vs 25%, P = 0.002) (Fig. 1). Similarly, patients in the ST group more often required invasive mechanical ventilation than patients in the TCZ group (32% vs 0%, P = 0.006). No statistical difference was observed between the two groups in terms of mortality, unlike ICU admissions; however, death clearly tended to be more frequent in the ST group than in the TCZ group (48% vs 25%, P = 0.066).

4. Discussion

Despite the small sample size and the retrospective nature of the work, the latter strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.

Our population seems to be older, with more comorbidities, and a higher level of mortality than other studies with COVID-19 patients [1,7]. This may be explained by our methodology (exclusion of patients without hospitalization criteria and with-out standard treatment) to select critically ill patients and have a comparable population with the TCZ group (which were critically ill patients).

Tocilizumab was administered on average 13 days after COVID-19 symptom onset, after failure of standard treatment, after a mean 7 days from admission, in patients with many comorbidities and critically ill (oxygen therapy flow average at 10L/min). However, compared with the ST group (which included fewer comorbid and critically ill patients), the occurrence of death and/or ICU admissions are clearly lower (25% versus 72%) with high statistical significance (P = 0.002) despite the low numbers of patients. None of our 20 TCZ-treated patients was hospitalized in the ICU. Finding enough ICU beds is highly challenging during the present COVID-19 pandemic [2]; TCZ could be key in the treatment of COVID-19 cases to reduce ICU admissions. It could also have a huge public health
Table 1
Comparison of demographic, clinical, paraclinical findings and outcome of both groups.

| Characteristics                                      | TCZ group (n = 20) | ST group (n = 25) | P-value |
|------------------------------------------------------|--------------------|-------------------|---------|
| Demographic characteristics                         |                    |                   |         |
| Age (y) [mean, range, SD]                            | 76.8 [52–93] ± 11  | 70.7 [33–96] ± 15 | 0.141   |
| [18–50]                                               | 0                  | 2 (8%)            | 0.303   |
| [51–70]                                               | 6 (30%)            | 12 (48%)          | 0.221   |
| [71–80]                                               | 5 (25%)            | 5 (20%)           | 0.688   |
| > 80                                                  | 9 (45%)            | 6 (24%)           | 0.138   |
| Male (Number, %)                                     |                    |                   |         |
| Current smoking (Number, %)                          | 2 (10%)            | 0                 | 0.192   |
| Charlson comorbidity index (mean, range, SD)         | 5.3 [1–10] ± 2.4   | 3.4 [0–9] ± 2.6   | 0.014   |
| Comorbidities (Number, %)                            |                    |                   |         |
| No comorbidity                                       | 4 (20%)            | 6 (24%)           | 1       |
| BMI (kg/m²)                                          | 26.1 [17–32] ± 4.3 | 27.2 [22–32] ± 3  | 0.503   |
| Hypertension                                         | 11 (55%)           | 13 (44%)          | 0.463   |
| Cardiovascular diseases<sup>a</sup>                  | 14 (70%)           | 17 (68%)          | 0.885   |
| Diabetes mellitus                                    | 5 (25%)            | 8 (32%)           | 0.607   |
| COPD<sup>b</sup>                                      | 4 (20%)            | 1 (4%)            | 0.155   |
| Immunosuppression<sup>c</sup>                        | 0                  | 0                 | 1       |
| Malignancy                                           | 7 (35%)            | 2 (8%)            | 0.057   |
| Clinical features at admission                       |                    |                   |         |
| q-SOFA<sup>d</sup>                                   | 0.25 [0–1] ± 0.44  | 0.44 [0–2] ± 0.58 | 0.235   |
| Blood pressure < 100 mmHg                           | 0                  | 1 (3%)            | 1       |
| Confusion or Glasgow scale < 15                      | 1 (5%)             | 3 (12%)           | 0.617   |
| Respiratory rate > 22 (Number, %)                    | 4 (20%)            | 6 (24%)           | 1       |
| Sat O₂ (%) [mean, range, SD]                         | 90 [62–98] ± 9     | 91 [78–100] ± 5   | 0.773   |
| Parachinical findings at admission                   |                    |                   |         |
| > 50% lung involvement on CT scan                    | 12 (60%)           | 2 (25%)           | 0.208   |
| Lyphocytes (mm³)                                     | 67[210–1730] ± 357 | 914[450–1620] ± 345 | 0.037   |
| C-reactive protein (mg/L)                            | 158[61–309] ± 70   | 105[13–271] ± 66  | 0.017   |
| Characteristics during hospitalization               |                    |                   |         |
| Positive PCR for SARS-CoV2 (respiratory samples)     | 19 (95%)           | 25 (100%)         | 0.444   |
| Highest level of oxygen therapy ≥ 24 h/L/min         | 13[5–15] ± 4       | 6[1–15] ± 4       | <0.001  |
| Duration of oxygen therapy (days)                    | 12[4–25] ± 6       | 4[1–10] ± 4       | 0.009   |
| Oxygen therapy flow at TCZ initiation (L/min)         | 10[5–15]           | NA                | NA      |
| Time from symptom onset to TCZ initiation (days)      | 13[4–21]           | NA                | NA      |
| Time from admission to TCZ initiation (days)          | 7[2–22]            | NA                | NA      |
| Outcome                                              |                    |                   |         |
| Death and/or ICU admission                           | 5 (25%)            | 18 (72%)          | 0.002   |
| Death                                                | 5 (25%)            | 12 (48%)          | 0.066   |
| ICU admission                                        | 0                  | 11 (44%)          | <0.001  |
| Invasive mechanical ventilation (IMV)                | 0                  | 8 (32%)           | 0.006   |
| Patients still hospitalized<sup>d</sup>               | 3 (15%)            | 2 (8%)            | 0.642   |
| Discharge                                            | 11 (55%)           | 11 (44%)          | 0.463   |
| Duration of hospitalization (days)                   | 13[4–32] ± 7       | 17 [5–41] ± 12   | 0.324   |

TCZ: tocilizumab; ST: standard treatment
<sup>a</sup> Defined by: cardiac failure, cardiac arrhythmia, coronary heart disease, stroke, peripheral arterial obstructive disease and thromboembolic disease.
<sup>b</sup> COPD: chronic obstructive pulmonary disease.
<sup>c</sup> Defined by: transplantation, cirrhosis, long-term steroids therapy, immunomodulators treatments and human immunodeficiency virus (HIV).
<sup>d</sup> For both group we collected outcome data’s until April 24<sup>e</sup> 2020.

---

**Fig. 1.** Outcome in the tocilizumab (TCZ) group and in the standard treatment (ST) group.
impact as well as an impact on reducing the human and economic cost of the outbreak. The low number of patients included in our work probably explains that the difference in mortality is not significant because of a lack of statistical power, but we can notice a clear trend for fewer deaths in the TCZ group.

Only a few cases and series reported that repeated doses of TCZ may improve the condition of critically ill patients [14–17]. A small clinical trial conducted in China including 21 severe COVID-19 patients treated by TCZ showed that clinical outcome was favorable in more than three quarters of patients. Laboratory findings such as lymphocytes and CRP levels returned to normal and the CT scan showed that the lung lesions of 19 patients resolved [18]. Only recently, Roumier et al. showed that treatment with TCZ significantly reduced the risk of subsequent ICU admission in 30 patients after weighted analysis [19], as in our study. Our study is retrospective with a low number of patients in each group. Larger prospective randomized trials are required to confirm these findings.

5. Conclusion

We showed that TCZ added to the “standard treatment” reduced intensive care unit admissions and/or mortality in COVID-19 patients. TCZ could be key in the treatment of severe COVID-19 patients. All hospitals should consider these findings.

Contributors

T.K., S.Z., and N.J.K.O. collected the epidemiological and clinical data. T.K. and S.Z. drafted the manuscript. V.G. and T.C. revised the final manuscript. A.L., J.C.B., J.B., P.Y.R., L.T., C.M., M.B., A.M.B., A.C., M.F.R., R.C. I.M., P.D. are all member of the “HNF Hospital Tocilizumab multidisciplinary team”.

Disclosure of interest

The authors declare that they have no competing interest.

We thank all patients involved in the study. We thank especially Dr Hajer Zahra, all the group study (HNF Hospital Tocilizumab multidisciplinary team) and the Clinical Research Unit of NFC Hospital (Bouvier Elodie and Charlotte Bourgoin) for their help.

References

[1] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.

[2] Phua J, Weng L, Ling L, Egi M, Lim C-M, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020.

[3] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): a review. Jama 2020.

[4] Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020;395(10229):1014–5.

[5] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med [Internet] 2020 [cited 26 avr 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164771/.

[6] Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020.

[7] Ruan Q, Yang K, Wang W, Jiang L, Song J. Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020.

[8] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020 [S0163445320301651].

[9] Siddiqui HK, Mehra MR. COVID-19 Illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant [Internet] 2020 [cited 29 avr 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116552/.

[10] Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med [Internet] 2020:18 [cited 26 avr 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154566/.

[11] Zhang C, Wu Z, Li J, W, Zhao H, Wang C-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;105954.

[12] Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2020;25(3).

[13] Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2020;25(6).

[14] Tocilizumab treatment in COVID-19: a single center experience. - PubMed - NCBI [Internet]. [cited 29 avr 2020]. Disponible sur : https://www.ncbi.nlm.nih.gov/pubmed/?term=Luo+P%2C+Liu+Y%2C+Qiu+L%2C+Liu+X%2C+Liu+D%2C+Xiaoling+et+al.%2C+2020.04.20.20061861.

[15] Michot J-M, Albigez L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 2020.

[16] Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv 2020;4(7):1307–10.

[17] Mihai C, Dobrota R, Schröder M, Garaian A, Jordan S, Becker MO, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 2020:79(5):668–9.

[18] Xiaoling Xu, Mingfeng Han, Tiantian Li, et al. Effective Treatment of severe COVID-19 patients with tocilizumab. http://www.chinaxiv.org/abs/202003.00020 [accessed April 27, 2020].

[19] Roumier M, Paule E, Groh M, Vaille A, Ackermann F, Interleukin-6 blockade for severe COVID-19. medRxiv 2020 [2020.04.20.20061861].